Eli Lilly expands manufacturing for popular drugs Zepbound and Mounjaro

Eli Lilly to invest $5 billion in Indiana site to increase production of popular weight-loss and diabetes treatments, Zepbound and Mounjaro.

Eli Lilly, a prominent pharmaceutical company, has announced a significant investment of over $5 billion to expand its manufacturing site in Indiana. This expansion aims to increase the production of two of its popular medications, Zepbound and Mounjaro, used for weight loss and diabetes treatment.

The company is doubling its investment in a site near its headquarters in Indianapolis, with plans to commence production at its Lebanon, Indiana plant by the end of 2026. The production is expected to ramp up through 2028, contributing to job creation and economic growth in the region.

The announcement was made at the Indiana Global Economic Summit by Governor Eric Holcomb, who praised Lilly for its contribution to the state's economy. This investment marks the largest manufacturing investment in Lilly's history, showcasing its commitment to innovation and growth.

The expanded facility in the LEAP Research and Innovation District will focus on producing tirzepatide, the key ingredient in both Zepbound and Mounjaro. These medications have shown promising results, with combined sales exceeding $2 billion in the first quarter of this year.

Despite the growing demand for these drugs, Lilly has faced challenges in meeting supply requirements. The expansion of the manufacturing site is expected to address this issue and support the company's future growth plans. Analysts predict that Zepbound and Mounjaro could generate over $30 billion in annual sales for Lilly, highlighting the potential impact of this investment.

Overall, this expansion represents a significant milestone for Lilly and the pharmaceutical industry, showcasing the company's commitment to innovation, job creation, and economic development in Indiana.